AbbVie Net Change in Property, Plant, and Equipment 2010-2025 | ABBV
AbbVie annual/quarterly net change in property, plant, and equipment history and growth rate from 2010 to 2025. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
- AbbVie net change in property, plant, and equipment for the quarter ending March 31, 2025 was $-0.235B, a 21.76% increase year-over-year.
- AbbVie net change in property, plant, and equipment for the twelve months ending March 31, 2025 was $-2.326B, a 22.74% increase year-over-year.
- AbbVie annual net change in property, plant, and equipment for 2024 was $-0.974B, a 25.35% increase from 2023.
- AbbVie annual net change in property, plant, and equipment for 2023 was $-0.777B, a 11.8% increase from 2022.
- AbbVie annual net change in property, plant, and equipment for 2022 was $-0.695B, a 11.69% decline from 2021.
AbbVie Annual Net Change in Property, Plant, and Equipment
(Millions of US $) |
| 2024 |
$-974 |
| 2023 |
$-777 |
| 2022 |
$-695 |
| 2021 |
$-787 |
| 2020 |
$-798 |
| 2019 |
$-552 |
| 2018 |
$-638 |
| 2017 |
$-529 |
| 2016 |
$-479 |
| 2015 |
$-532 |
| 2014 |
$-612 |
| 2013 |
$-491 |
| 2012 |
$-333 |
| 2011 |
$-356 |
| 2010 |
$-448 |
| 2009 |
$-313 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$326.520B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
